Univercells

Univercells

Univercells is a Belgium-based bio manufacturing company founded in 2013.

Univercells is a company offering bio manufacturing solutions in Belgium. The company develops automated cell culture and virus production bioreactors for biotechnology and healthcare sectors. Founded 2013 in Gosselies, Hainaut, Belgium by Hugues Bultot, Univercells has raised a total of $94.5M in funding over six rounds. Their latest funding was raised on February 18, 2020 from a venture round. The company is funded by 10 investors, with Kohlberg Kravis Roberts and ClubDeal as its most recent investors. It delivers novel bio-manufacturing platforms and solutions aimed at making biologics available and affordable by relying on proprietary core technologies and a continuous process intensification approach.

Univercells launched Exothera, a contract development and manufacturing organization (CDMO), in March, 2020 that will focus on viral vectors targeting cell and gene therapy and vaccine development. Exothera will run in Jumet Belgium. Exothera services will include helping companies streamline development and production of viral vectors and building custom commercial facilities on site. Exothera plans to work on vaccines for COVID-19 through supporting vaccine innovators and providing manufacturing services.

Timeline

July 2018

Univercells raises a $18,800,000 series B round from Global Health Investment Fund.

December 2017

Univercells raises a $3,560,000 series A round from Takeda Ventures.

2013

Founded

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
2 Results
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Hugues Bultot

Founder & CEO

Rodolphe de Spoelberch

Board Member

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Changing the Biomanufacturing Paradigm

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.